- A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
-
Lee J, Kim J, Ghang B, Jeong W
- KMID: 2541929
- Korean J Intern Med.
- 2023 May;38(3):427-433.
- doi: 10.3904/kjim.2022.190
Background/Aims: The occurrence of gout attacks at the start of uric acid lowering treatment worsens compliance. We aimed to determine the appropriate dose of febuxostat to reduce the occurrence of... -
- CITED
-
- Close
- SHARE
-
- Close
- Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
-
Waheed Y, Yang F, Sun D
- KMID: 2521724
- Korean J Intern Med.
- 2021 Nov;36(6):1281-1293.
- doi: 10.3904/kjim.2020.340
Previous research has investigated whether hyperuricemia serves as an independent risk factor for cardiovascular and renal diseases. Hyperuricemia is defined as an abnormally high level of uric acid (UA; i.e.,... -
- CITED
-
- Close
- SHARE
-
- Close
- Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4–5 chronic kidney disease not yet on dialysis
-
Kim SH, Lee SY, Kim JM, Son CN
- KMID: 2504191
- Korean J Intern Med.
- 2020 Jul;35(4):998-1003.
- doi: 10.3904/kjim.2018.423
Background/Aims: The safety and efficacy of febuxostat in patients with stage 4–5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. Therefore, we... -
- CITED
-
- Close
- SHARE
-
- Close
- What is the Best Choice for Urate-lowering Therapy for Korean?
-
Cheon YH, Song JS
- KMID: 2471948
- J Rheum Dis.
- 2020 Apr;27(2):78-87.
- doi: 10.4078/jrd.2020.27.2.78
Gout is one of the most common forms of acute inflammatory arthritis caused by long-standing hyperuricemia. Various clinical and epidemiological studies have demonstrated that uric acid, which is strongly associated... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of Efficacy and Safety of Febuxostat in Gout Patients with Chronic Kidney Disease Stage 3 and Stage 4/5
-
Ahn E, Lee S, Lee HN, Lee SG, So MW
- KMID: 2442022
- J Rheum Dis.
- 2019 Apr;26(2):118-123.
- doi: 10.4078/jrd.2019.26.2.118
OBJECTIVE: To compare efficacy and safety of febuxostat in gouty patients with chronic kidney disease (CKD) stage 3 and stage 4/5. METHODS: Age and sex matched patients with CKD stage 3... -
- CITED
-
- Close
- SHARE
-
- Close
- Renoprotective effects of febuxostat compared with allopurinol in patients with hyperuricemia: A systematic review and meta-analysis
-
Kim S, Kim HJ, Ahn HS, Oh SW, Han KH, Um TH, Cho CR, Han SY
- KMID: 2416097
- Kidney Res Clin Pract.
- 2017 Sep;36(3):274-281.
- doi: 10.23876/j.krcp.2017.36.3.274
BACKGROUND: Hyperuricemia is reported to be related to rapid progression of renal function in patients with chronic kidney disease (CKD). Allopurinol, a uric acid lowering agent, protects renal progression. However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparative Efficacy and Safety of Febuxostat and Allopurinol in the Treatment of Hyperuricemia: A Bayesian Network Meta-analysis
-
Song GG, Lee YH
- KMID: 2222809
- J Rheum Dis.
- 2015 Dec;22(6):356-365.
- doi: 10.4078/jrd.2015.22.6.356
OBJECTIVE: The aim of this study was to assess the relative urate-lowering efficacy and safety of febuxostat and allopurinol in hyperuricemic patients with or without gout. METHODS: Randomized controlled trials (RCTs)... -
- CITED
-
- Close
- SHARE
-
- Close
- Febuxostat for the Treatment of Chronic Tophaceous Gout in a Patient on Continuous Ambulatory Peritoneal Dialysis
-
Yun JH, Kim HY, Kim DH, Oh JS, Kim SM, Sin YH, Kim JK
- KMID: 2269035
- Korean J Med.
- 2015 Aug;89(2):229-232.
- doi: 10.3904/kjm.2015.89.2.229
Hyperuricemic patients with gouty arthritis or tophi, a serum uric acid concentration of 8.0 mg/dL or higher, and complications should be treated with urate-lowering drugs. Conventionally, allopurinol is used to... -
- CITED
-
- Close
- SHARE
-
- Close
- Four-Week Effects of Allopurinol and Febuxostat Treatments on Blood Pressure and Serum Creatinine Level in Gouty Men
-
Kim HA, Seo YI, Song YW
- KMID: 2129601
- J Korean Med Sci.
- 2014 Aug;29(8):1077-1081.
- doi: 10.3346/jkms.2014.29.8.1077
The aim of this study was to observe the effects of uric acid lowering therapy (UALT), febuxostat and allopurinol, on blood pressure (BP) and serum creatinine level. Post-hoc data were... -
- CITED
-
- Close
- SHARE
-
- Close
- The Urate-lowering Efficacy and Safety of Febuxostat in Korean Patients with Gout
-
Park SH, Song YW, Park W, Koh EM, Yoo B, Lee SK, Yoo DH, Lee YJ, Kim HA, Choi HJ, Kim HY, Jung HG
- KMID: 2297536
- J Rheum Dis.
- 2013 Aug;20(4):223-230.
- doi: 10.4078/jrd.2013.20.4.223
OBJECTIVE: To compare the urate-lowering efficacy and the safety of febuxostat, allopurinol and placebo in Korean patients with gout for 4 weeks. METHODS: Subjects (n=182) with gout were randomized to febuxostat... -
- CITED
-
- Close
- SHARE
-
- Close
